Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | FPR1 | P21462 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367610 | 0.84 | HSD11B1 (0.35) | FPR1FPR2 | |
| SCHEMBL28347181 | 0.80 | SMN1; SMN2 (0.33) | MEN1KMT2AFPR1FPR2SMN1; SMN2 | |
| SCHEMBL16375061 | 0.77 | GPR119 (0.37) | DRD2 | |
| SCHEMBL17664671 | 0.71 | MEN1 (0.37) | MEN1KMT2ADRD2GAASMN1; SMN2 | |
| SCHEMBL16346678 | 0.71 | GPR52 (0.39) | FPR1FPR2 | |
| SCHEMBL30550464 | 0.69 | ACHE (0.39) | MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL17542683 | 0.67 | ALDH1A1 (0.37) | MEN1KMT2A | |
| SCHEMBL19752740 | 0.66 | MEN1 (0.37) | MEN1KMT2AAOC3DRD2GAA | |
| SCHEMBL7133599 | 0.65 | CYP11B1 (0.51) | KMT2A | |
| SCHEMBL13139310 | 0.63 | HTR2A (0.44) | MEN1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326985-B2 | Heteroaryl pyridone and aza-pyridone amide compounds | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150011461-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS | GENENTECH, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| WO-2015000949-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011461-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS | BTK, TYK2, LCK | MEN1 2984/4885KMT2A 1803/4885AOC3 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.